conclude that the suitability of atenolol as an antihypertensive agent is now uncertain. Its role as a reference drug in trials of antihypertensive agents might no longer be appropriate.
The β-blocker atenolol is used widely as a first-line treatment for hypertension and as a reference drug in clinical trials. Prompted by a finding that the angiotensin-receptor blocker losartan ...